AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 222 min read$TEVA

Shields Matthew sold $322K of TEVA

Shields Matthew (EVP, Global Operations) sold 9,989 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $32.19 ($0.32M total) on 2026-06-18.

Original reporting
SEC EDGAR · Shields Matthew
Published Jun 22, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Neutral
low confidence
Mentioned
$TEVA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and post-transaction holdings (0 shares), which may slightly influence sentiment but does not change TEVA fundamentals in the text.

02

Market read

Traders may note the insider selling signal, but the disclosure alone is unlikely to be a standalone catalyst.

03

What to watch

No 10b5-1 plan is indicated, but the article also lacks context on total holdings history, tax events, or whether other insiders made offsetting buys.

Relevance 4/10Novelty 4/10Timing: after-hours/filing date (2026-06-22) for an insider sale executed 2026-06-18

Background

This is an SEC Form 4 insider transaction for TEVA, reported by Matthew Shields (EVP, Global Operations).

Company-level read

Ticker impact

$TEVANeutralLow confidence
Context

TEVA disclosed an EVP Global Operations open-market sale of 9,989 shares at $32.1901 on 2026-06-18 via Form 4.

Expected impact

Likely limited near-term impact; any effect would be small and quickly absorbed unless followed by additional disclosures.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated and no accompanying operational/financial guidance change.

Market effects

Sector

No sector read-across; this is company-specific insider transaction disclosure.

Regional

None indicated; TEVA is the only subject with a disclosed transaction.

Global

Minimal; no deal, regulatory action, or operational update is described.

Counterpoint

What could challenge this read

The sale could be liquidity/portfolio rebalancing rather than a bearish signal, especially since the transaction is labeled open-market and the filing provides no stated reason.

Key entities

  • issuer
    TEVA PHARMACEUTICAL INDUSTRIES LTD

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Shields Matthew

    EVP, Global Operations who sold 9,989 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min